UroGen Pharma insider files to sell ~0.01% float on 28 Jul 2025

Rhea-AI Filing Summary

Form 144 filed for UroGen Pharma Ltd. (URGN) reports a planned insider disposition.

• Securities: 5,149 ordinary shares.
• Estimated value: $97,573.55.
• Broker: Oppenheimer & Co., NASDAQ execution targeted for 28 Jul 2025.
• Total shares outstanding: 46,107,451; proposed sale equals ~0.011% of float.
• Share origin: Restricted Stock Units granted 31 Jan 2024 (10,000 units).
• Prior activity: Same seller disposed of 5,162 shares for $38,043.94 on 9 Jun 2025.

The filer certifies no undisclosed adverse information under Rule 144. Given the modest volume relative to outstanding shares, the transaction is unlikely to have a material price impact but continues a pattern of insider selling that investors may monitor.

Positive

• None.

Negative

• Insider intends to sell 5,149 shares (~0.011% of outstanding), highlighting continued divestiture.
• The same holder sold 5,162 shares in June 2025, indicating a short-term selling trend.

Insights

Portfolio Manager

TL;DR: Minor insider sale (~0.01% float); negligible market impact, but continued selling trend worth tracking.

The proposed sale of 5,149 shares represents a fractional 0.011% of UroGen’s outstanding equity, making liquidity impact minimal. Dollar value is modest at <$100k. However, it follows a June sale of a similar size, signalling an ongoing effort by the holder to monetize RSUs granted in January 2024. While such diversification is common, repeated filings can weigh on sentiment if they persist. Overall impact on valuation or float dynamics is neutral, yet trend monitoring is prudent.

Corporate Governance Analyst

TL;DR: Repeat Form 144 shows insider cash-out of RSUs; governance concerns low, disclosure standard.

Rule 144 filings provide transparency into insider intentions. The seller affirms no undisclosed adverse information, and the RSU source suggests compensation, not strategic exit. Volume is immaterial versus 46.1 M shares outstanding, limiting governance or control implications. Because transactions occur through a reputable broker on NASDAQ, execution risk is low. Overall, the filing is routine with neutral governance impact.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	5149	97573.55	46107451	07/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	01/31/2024	Restricted Stock Units	From the Issuer			10000	01/31/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Schoenberg 9 HA'TA'ASIYA ST RA'ANANA L3 4365007	Ordinary	06/09/2025	5162	38043.94

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many URGN shares are being sold under this Form 144?

The filing covers 5,149 ordinary shares.

What is the approximate value of the planned URGN share sale?

The shares are valued at $97,573.55 based on the market price used in the filing.

When is the planned sale date for the URGN shares?

The filer lists an approximate sale date of 28 July 2025.

What percentage of UroGen Pharma’s float does 5,149 shares represent?

With 46,107,451 shares outstanding, the sale equals about 0.011% of the float.

Has this insider sold URGN shares recently?

Yes. 5,162 shares were sold on 9 June 2025 for $38,043.94.

Which broker will handle the URGN share sale?

The broker of record is Oppenheimer & Co. Inc. at 85 Broad St., New York.

Where will the URGN shares be sold?

The filing indicates the shares will be sold on the NASDAQ exchange.